ANALIZA PROBLEMA VEZANIH ZA PRIMENU LEKOVA (DRUG-RELATED PROBLEMS) KOD PACIJENATA SA GASTROEZOFAGEALNOM REFLUKSNOM BOLEŠĆU LEČENIH INHIBITORIMA PROTONSKE PUMPE

Jelena D Milutinović; Filip Martinović

doi:10.5937/racter7-8699

Jelena D Milutinović Univerzitet u Kragujevcu, Fakultet medicinskih nauka
Filip Martinović Faculty of Medical Sciences, University of Kragujevac

DOI: https://doi.org/10.5937/racter7-8699

Ključne reči: proton pump inhibitors||, ||blokatori protonske pumpe, Drug-Related Problems||, ||Drug-Related Problems, CYP 450 2C19||, ||CYP 450 2C19, CYP 450 3A4||, ||CYP 450 3A4,

Sažetak

Uvod: Problemi vezani za primenu lekova su veoma česti u svim terapijskim oblastima.

Cilj rada: Otkrivanje problema vezanih za primenu lekova kod pacijenata sa gastroezofagelanim refluksom i analiza njihove eventualne povezanosti sa karakteristikama pacijenata.

Materijal i metod: Sprovedena je deskriptivna, retrospektivna studija preseka radi utvrđivanja najčešćih problema vezanih za primenu lekova kod pacijenata sa gastroezofagealnim refluksom koji se leče inhibitorima protonske pumpe. Istraživanje je sprovedeno na odeljenju gastroenterologije u Kliničkom centru u Kragujevcu. Obuhvaćeni su svi pacijenti koji su na tom odeljenju lečeni od gastroezofagealne refluksne bolesti, a kao terapiju su koristili inhibitore protonske pumpe u periodu od 1.1.2014. godine do 1.1.2015. godine. U radu je korišćena deskriptivna statistika (procentualna zastupljenost, srednja vrednost i standardna devijacija). Takođe je određena korelacija između broja neželjenih događaja i karakteristika pacijenata.

Rezultati: Prosečna starost pacijenata bila je 55,97 ± 15,81 godina, a 43 (60,6 %) pacijenata bilo je muškog pola. Prosečna dužina hospitalizacije bila je 12,30 ± 8,89 dana. Pronađeno je ukupno 182 problema po klasifikaciji Pharmaceutical Care Network Europe, i u proseku je bilo 2,56 problema po pacijentu. Samo 5 (7%) pacijenata nije imalo nijedan problem, dok je 11 (15,49%) pacijenata imalo preko 10 mogućih interakcija između lekova. Najčešće kategorije problema koji su se javili jesu neadekvatan izbor leka, neodgovarajuća upotreba leka i interakcije između lekova.

Zaključci: Moguće interakcije između lekova, kao i o drugi problemi vezani za inhibitore protonske pumpe su veoma česti kod pacijenata sa GERB-om. Identifikacija različitih podtipova problema vezanih za primenu lekova, kao i faktora koji mogu biti povezani sa njima, može uticati na smanjenje rizika od nepovoljnih ishoda lečenja pacijenata sa gastroezofagealnom refluksnom bolešću koji koriste blokatore protonske pumpe.

Biografije autora

Jelena D Milutinović, Univerzitet u Kragujevcu, Fakultet medicinskih nauka

Student integrisanih akademskih studija farmacije

Filip Martinović, Faculty of Medical Sciences, University of Kragujevac

Student

Reference

Sugimoto M, Shirai N, Nishino M, et al. Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese. Eur J Clin Pharmacol. 2014; 70 (9): 1073-8.

Ratin AC, Orso IR. Minimal endoscopic changes in non-erosive reflux disease. Arq Bras Cir Dig. 2015; 28 (1): 20-3.

Pyun JE, Choi da M, Lee JH, Yoo KH, Shim JO. Achalasia Previously Diagnosed as Gastroesophageal Reflux Disease by Relying on Esophageal Impedance-pH Monitoring: Use of High-Resolution Esophageal Manometry in Children. Pediatr Gastroenterol Hepatol Nutr. 2015; 18 (1): 55-9.

Falk GL, Beattie J, Ing A, et al. Scintigraphy in laryngopharyngeal and gastroesophageal reflux disease: A definitive diagnostic test? World J Gastroenterol. 2015; 21 (12): 3619-27.

Pharmaceutical Care Network Europe Foundation. (2006) PCNE Classification for Drug Related Problems Version 5.01. Available: http://www.pcne.org/sig/ drp/documents/PCNE%20classification%20V5.01.pdf, Accessed 09 July 2014.

Page II RL, Ruscin JM. The risk of adverse drug events and hospital-related morbidity and mortality among older adults with potentially inappropriate medication use. The American Journal of Geriatric Pharmacotherapy 2006; 4 (4): 297–305.

Silva C, Ramalho C, Luz I, Monteiro J, Fresco P. Drug-related problems in institutionalized, polyme-dicated elderly patients: opportunities for pharmacist intervention. Int J Clin Pharm. 2015; 37 (2): 327-34.

Planas LG, Kimberlin CL, Segal R, et al. A pharmacist model of perceived responsibility for drug therapy outcomes. Social Science & Medicine 2005; 60: 2393–403.

Jensen RT. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol. 2006; 98 (1): 4-19.

van Roozendaal BW, Krass I. Development of an evidence-based checklist for the detection of drug related problems in type 2 diabetes. Pharmacy World and Science 2009; 31: 580–95.

Zaman Huri H, Hoo FW. Drug related problems in type 2 diabetes patients with hypertension: A cross-sectional retrospective study. BMC Endocrine Disorders 2013; 13 (2): 1-25.

Bjorkman IK, Sanner MA, Bernsten CB. Comparing 4 classification systems for drug-related problems: processes and functions. Res. Soc. Adm. Pharm. 2008; 4: 320–31.

Lampert ML, Kraehenbuehl S, Hug BL. Drug-related problems: evaluation of a classification system in the daily practice of a Swiss University hospital. Pharm World Sci 2008; 30: 768–76.

Van Mil JW, Westerlund LO, Hersberger KE, Schaefer MA. Drug-relatedproblem classification systems. Ann Pharmacother 2004; 38: 859–67.

Zaman Huri H, Hui Xin C, Sulaiman CZ. Drug-Related Problems in Patients with Benign Prostatic Hyper-plasia: A Cross Sectional Retrospective Study. PLoS ONE 2014; 9(1): e86215.

Drug Interaction Checker, Available at: http://reference.medscape.com/drug-interactionchecker

Al-Arifi M, Abu-Hashem H, Al-Meziny M, Said R, Aljadhey H. Emergency department visits and admissions due to drug related problems at Riyadh military hospital (RMH), Saudi Arabia. Saudi Pharm J. 2014; 22 (1): 17-25.

Chan A, Soh D, Ko Y, Huang YC, Chiang J. Characteristics of unplanned hospital admissions due to drug-related problems in cancer patients. Support Care Cancer. 2014; 22 (7): 1875-81.

Urbina O, Ferrández O, Luque S, еt al. Patient risk factors for developing a drug-related problem in a cardiology ward. Ther Clin Risk Manag. 2014; 11: 9-15.

Raimbault-Chupin M, Spiesser-Robelet L, Guir V, et al. Drug related problems and pharmacist interventions in a geriatric unit employing electronic prescribing. Int J Clin Pharm. 2013; 35 (5): 847-53.

Westerlund T, Gelin U, Pettersson E, Skärlund F, Wågström K, Ringbom C. A retrospective analysis of drug-related problems documented in a national database. Int J Clin Pharm. 2013; 35 (2): 202-9.

Willoch K, Blix HS, Pedersen-Bjergaard AM, Eek AK, Reikvam A. Handling drug-related problems in rehabilitation patients: a randomized study. Int J Clin Pharm. 2012; 34 (2): 382-8.